Agilon Health (AGL) to Release Earnings on Wednesday

Agilon Health (NYSE:AGL) will likely be posting its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $1.4614 billion for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, February 25, 2026 at 4:30 PM ET.

Agilon Health Stock Performance

NYSE:AGL opened at $0.44 on Monday. Agilon Health has a 52 week low of $0.34 and a 52 week high of $6.08. The firm has a 50-day moving average price of $0.73 and a two-hundred day moving average price of $0.87. The firm has a market cap of $181.71 million, a price-to-earnings ratio of -0.58 and a beta of 0.06.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AGL. CIBC Bancorp USA Inc. purchased a new stake in shares of Agilon Health during the third quarter worth $34,000. Tower Research Capital LLC TRC raised its stake in shares of Agilon Health by 214.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 37,079 shares of the company’s stock valued at $85,000 after purchasing an additional 25,270 shares during the period. Prudential Financial Inc. lifted its holdings in Agilon Health by 70.7% during the 2nd quarter. Prudential Financial Inc. now owns 40,880 shares of the company’s stock worth $94,000 after purchasing an additional 16,928 shares in the last quarter. LPL Financial LLC lifted its holdings in Agilon Health by 213.4% during the 4th quarter. LPL Financial LLC now owns 44,055 shares of the company’s stock worth $30,000 after purchasing an additional 30,000 shares in the last quarter. Finally, WINTON GROUP Ltd bought a new position in Agilon Health in the 2nd quarter worth about $106,000.

Analyst Upgrades and Downgrades

AGL has been the topic of a number of recent analyst reports. Royal Bank Of Canada upgraded Agilon Health from a “hold” rating to a “moderate buy” rating in a report on Wednesday, December 3rd. Barclays decreased their target price on Agilon Health from $1.50 to $1.00 and set an “underweight” rating for the company in a research report on Thursday, November 6th. Wells Fargo & Company cut their price target on shares of Agilon Health from $1.50 to $1.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Agilon Health in a research report on Wednesday, January 21st. Finally, BTIG Research restated a “neutral” rating on shares of Agilon Health in a report on Friday, December 12th. Four investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Agilon Health has a consensus rating of “Hold” and an average target price of $2.71.

More Agilon Health News

Here are the key news stories impacting Agilon Health this week:

• Neutral Sentiment: Market context: AGL has seen increased trading activity and a short‑term price uptick despite the legal filings; that bounce may reflect low float, speculative trading or short covering rather than a change in fundamentals.
• Negative Sentiment: Rosen Law Firm reminds purchasers of AGL of the March 2, 2026 lead‑plaintiff deadline and is soliciting investors who suffered losses during the alleged class period — this is part of a coordinated push to identify lead plaintiffs and pursue a securities suit. Rosen Law Firm Notice
• Negative Sentiment: Multiple national firms (Pomerantz, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, Levi & Korsinsky, The Gross Law Firm, Bernstein Liebhard, Kirby McInerney, Schall, etc.) have filed or issued investor notices seeking plaintiffs and claiming investor harm — the accumulation of these actions raises potential litigation, defense costs, and settlement risk for AGL. Representative PR Newswire Notice
• Negative Sentiment: Practical impact for investors: if a lead plaintiff is appointed and the litigation proceeds, AGL could face material legal liabilities, increased governance scrutiny, and downward pressure on the share price; monitor SEC filings, company disclosures, and any governmental inquiries closely. Bronstein Notice

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.